Background/Aim. Depersonalization is considered to be the third leading symptom in psychiatric morbidity. The aim of this study was to investigate the correlation of depersonalization and different patterns of suicidal behaviour in patients suffering from depresssive disorder. Methods. The study included 119 depressed patients divided into two groups: the first group consisted of depressed patients with clinically manifested depersonalization according to the Cambridge Depresonalisation Scale presented score ≥ 70, and the second group consisted of the patients whithout clinically manifested depersonalization symptomatology, or, it was on the subsyndromal level. Subsequently, these two groups were compared regarding the suicidality indicators. Results. According to the Scale for Suicide Ideation of Beck, the depressed patients with depersonalization had statistically significantly higher scores regarding suicidal ideation, both active and passive, more often manifested suicidal desire, suicidal planning and overall suicidality (p < 0.000). Positive ideation, as a protective factor, was reduced in this group (p < 0.000). These patients had more previous suicide attempts (p < 0.001) and family history of suicides (p = 0.004). The depressed patients with depersonalization had 8 times more often active suicidal desire, 11 times more often passive suicidal desire and 5 times more often suicidal planning compared to patients without depersonalization. Conclusion. Suicidal potential, manifested in various patterns of suicidal behaviour among the patients suffering from depressive disorder with clinically manifested depersonalization is prominent. It is necessary to pay particular attention to depersonalization level during diagnostic and treatment procedure of the depressed patients having in mind that it may be associated with high suicidal potential.
This was an eight months prospective study.Study was active controlled in patients who were hospitalized in our Clinic. Schizophrenia was diagnosed by using PANSS scale and by using MKB 10 criteria. Laboratory data were measured at baseline, every month after therapy and at endpoint. Laboratory tests included glucose level in serum and OGTT, which were determined from blood, before breakfast and in the same hospital laboratory. Patients with family history of diabetes mellitus were excluded from the study.A total of 30 patients were recruited. the risperidone shows clinically insignificant effect on plasma glucose levels. Incidence of new onset diabetes was abaut 5% higher with olanzapine than risperidone, and the biggest increasing was in first three months. Elevated serum glucose levels have been shown with clozapine and dose-related effects were noted. We also found modest, but significant risk for increasing plasma glucose levels in patients with chlorpromazine medication. Lack of relationship between serum levels of zuclopentixol and plasma glucose has been shown. There are no apparent problems with sulpiride and with haloperidol. Medication with chlorpromazine did not show any significant modifications to blood glucose levels.The antipsychotics appear to be associated with the development of glucose intolerance, new-onset diabetes mellitus and exacerbation of existing diabetes mellitus. These disturbances in glucose metabolism have their own medical consequences. Thus, to minimize morbidity and mortality associated with the use of antipsychotic medications, close screening and monitoring for diabetes mellitus should become a priority for all clinicians treating schizophrenia patients receiving antipsychotic therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.